Low-frequency repetitive transcranial magnetic stimulation on Parkinson motor function: a meta-analysis of randomised controlled trials

被引:40
作者
Zhu, HongCan [1 ]
Lu, ZhaoMing [3 ]
Jin, YiTing [1 ]
Duan, XiaoJia [1 ]
Teng, JunFang [1 ]
Duan, DongXiao [2 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou 45001, Peoples R China
[2] Zhengzhou Univ, Dept Physiol, Zhengzhou 45001, Henan, Peoples R China
[3] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 45001, Henan, Peoples R China
关键词
Parkinson's disease; PD; repetitive transcranial magnetic stimulation; rTMS; TMS; TREATING MAJOR DEPRESSION; BRAIN-STIMULATION; DISEASE; RTMS; THERAPY; SAFETY;
D O I
10.1017/neu.2014.43
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Objectives: Previous studies have demonstrated inconsistent findings regarding the efficacy of low-frequency repetitive transcranial magnetic stimulation (rTMS) in treating motor symptoms of Parkinson's disease (PD). Therefore, this meta-analysis was conducted to assess the efficacy of low-frequency rTMS. Methods: A comprehensive literature search (including PubMed, CCTR, Embase, Web of Science, CNKI, CBM-disc, NTIS, EAGLE, Clinical Trials, Current Controlled Trials, International Clinical Trials Registry) was conducted dating until June 2014. The key search terms ('Parkinson', 'PD', 'transcranial magnetic stimulation', 'TMS', 'RTMS' and 'noninvasive brain stimulation') produced eight high-quality randomised controlled trials (RCT) of low-frequency rTMS versus sham stimulation. Results: These eight studies, composed of 319 patients, were meta-analysed through assessment of the decreased Unified Parkinson's Disease Rating Scale (UPDRS part III) score. Pooling of the results from these RCTs yielded an effect size of -0.40 (95% CI = -0.73 to -0.06, p<0.05) in UPDRS part III, which indicated that low-frequency rTMS could have 5.05 (95% CI = -1.73 to -8.37) point decrease in UPDRS part III score than sham stimulation. Discussion: Low-frequency rTMS had a significant effect on motor signs in PD. As the number of RCTs and PD patients included here was limited, further large-scale multi-center RCTs were required to validate our conclusions.
引用
收藏
页码:82 / 89
页数:8
相关论文
共 37 条
[1]  
[Anonymous], MOD J NEURD NEUROSUR
[2]  
[Anonymous], 2001, J Neurol, DOI DOI 10.1007/PL00007826
[3]  
[Anonymous], CHINESE J PRACTICAL
[4]   Intermittent theta-burst transcranial magnetic stimulation for treatment of Parkinson disease [J].
Benninger, D. H. ;
Berman, B. D. ;
Houdayer, E. ;
Pal, N. ;
Luckenbaugh, D. A. ;
Schneider, L. ;
Miranda, S. ;
Hallett, M. .
NEUROLOGY, 2011, 76 (07) :601-609
[5]   Bilateral vs. unilateral repetitive transcranial magnetic stimulation in treating major depression: A meta-analysis of randomized controlled trials [J].
Chen, Jian-jun ;
Liu, Zhao ;
Zhu, Dan ;
Li, Qi ;
Zhang, Hongzhi ;
Huang, Hua ;
Wei, Youdong ;
Mu, Jun ;
Yang, Deyu ;
Xie, Peng .
PSYCHIATRY RESEARCH, 2014, 219 (01) :51-57
[6]   Left versus right repetitive transcranial magnetic stimulation in treating major depression: A meta-analysis of randomised controlled trials [J].
Chen, Jianjun ;
Zhou, Chuanjuan ;
Wu, Bo ;
Wang, Ying ;
Li, Qi ;
Wei, Youdong ;
Yang, Deyu ;
Mu, Jun ;
Zhu, Dan ;
Zou, Dezhi ;
Xie, Peng .
PSYCHIATRY RESEARCH, 2013, 210 (03) :1260-1264
[7]   Safety of different inter-train intervals for repetitive transcranial magnetic stimulation and recommendations for safe ranges of stimulation parameters [J].
Chen, R ;
Gerloff, C ;
Classen, J ;
Wassermann, EM ;
Hallett, M ;
Cohen, LG .
ELECTROMYOGRAPHY AND MOTOR CONTROL-ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY, 1997, 105 (06) :415-421
[8]   Epidemiology of Parkinson's disease [J].
de Lau, Lonneke M. L. ;
Breteler, Monique M. B. .
LANCET NEUROLOGY, 2006, 5 (06) :525-535
[9]   Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 [J].
Dorsey, E. R. ;
Constantinescu, R. ;
Thompson, J. P. ;
Biglan, K. M. ;
Holloway, R. G. ;
Kieburtz, K. ;
Marshall, F. J. ;
Ravina, B. M. ;
Schifitto, G. ;
Siderowf, A. ;
Tanner, C. M. .
NEUROLOGY, 2007, 68 (05) :384-386
[10]   Afatinib: First Global Approval [J].
Dungo, Rosselle T. ;
Keating, Gillian M. .
DRUGS, 2013, 73 (13) :1503-1515